中文产业新闻· GlobeNewswire·· 21 hours agoScore68
argenx to Present Phase 3 ALKIVIA Results in Autoimmune Myositis as a Latereaking Oral Presentation at ACR Convergence 2026
In brief
argenx announced that Phase 3 ALKIVIA data for efgartigimod in autoimmune myositis will be presented as a late-breaking oral presentation (#LB24) at ACR Convergence 2026.
Source: 中文产业新闻 · globenewswire.com